Background illustration for clinical trials search

Paid Clinical Trials Santa Fe

Discover 306 paid clinical trials in Santa Fe, New Mexico. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 306

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Albuquerque NM, Highlands Ranch CO, Aurora CO,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for

Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular,

Location: Albuquerque NM, Lubbock TX, El Paso TX, Denver CO,

Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT03126916

Phase3, Recruiting

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

for

Endometrial Endometrioid Adenocarcinoma,

Location: Albuquerque NM, Iowa City IA

Sponsor: New Mexico Cancer Research Alliance

Sex: Female

Age: 18+

Code: NCT07436793

Phase2, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Albuquerque NM, Oklahoma City OK, Salt Lake City UT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase2, Recruiting

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

for

Hematopoietic and Lymphatic System Neoplasm,

Location: Albuquerque NM, Garden City KS, Phoenix AZ,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06279013

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Albuquerque NM, Oklahoma City OK, Las Vegas NV,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for

Pancreatic Neoplasm

Location: Albuquerque NM, Scottsdale AZ, Phoenix AZ,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 50 - 70+

Code: NCT04239573

Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Albuquerque NM, Edwards CO, Scottsdale AZ, Gilbert AZ,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06532279

Phase2, Recruiting

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for

B Acute Lymphoblastic Leukemia

Location: Albuquerque NM, Lubbock TX, El Paso TX, Aurora CO,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 46

Code: NCT06124157

Phase2, Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

for

Pancreatic Neuroendocrine Tumor (pNET),

Location: Albuquerque NM, Phoenix AZ, Tucson AZ,

Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT06943755

Phase2, Phase3, Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for

Endometrial Cancer

Location: Albuquerque NM, Fort Worth TX, Tulsa OK, San Antonio TX,

Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06952504

Phase3, Recruiting

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for

Hematopoietic and Lymphatic System Neoplasm,

Location: Albuquerque NM, El Paso TX, Aurora CO, Mesa AZ,

Sponsor: Children's Oncology Group

Sex: All

Age: 15 - 20

Code: NCT06410209

Phase2, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: Albuquerque NM, Loveland CO, Greeley CO,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for

Metastatic Salivary Gland Carcinoma,

Location: Albuquerque NM, Highlands Ranch CO, Aurora CO, Hays KS,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05408845

Phase2, Recruiting

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for

Metastatic Clear Cell Renal Cell Carcinoma,

Location: Albuquerque NM, Garden City KS, Gilbert AZ, Tucson AZ,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04510597

Phase3, Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia,

Location: Albuquerque NM, Phoenix AZ, Tucson AZ, Oklahoma City OK,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase2, Recruiting

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for

Malignant Solid Neoplasm

Location: Albuquerque NM, Overland Park KS, Westwood KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642611

Phase3, Recruiting

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for

Cardiotoxicity, HER2/Neu Positive,

Location: Albuquerque NM, Hays KS, Fort Worth TX, Richardson TX,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT03418961

Phase3, Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Albuquerque NM, Tucson AZ, Oklahoma City OK,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554393

Phase2, Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

for

Non-Small Cell Lung Cancer (NSCLC)

Location: Albuquerque NM, Irving TX, Houston TX, Santa Barbara CA,

Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT05920356

Phase3, Recruiting

Paid Clinical Trials Santa Fe

Filter results

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

Interested in new trials?

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)